Skip to content
Adam Torkildson – Lifestyle
Author:
Castle Biosciences, Inc.
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
March 9, 2026
←
Previous Page
1
2